Cornerstone Strategic Value Fund
Change company Symbol lookup
Select an option...
CLM Cornerstone Strategic Value Fund
RCI Rogers Communications Inc
ADRA Adara Acquisition Corp
EVTC Evertec Inc
OPEN Opendoor Technologies Inc
XAIR Beyond Air Inc
CXE MFS High Income Municipal Trust
CWGL Crimson Wine Group Ltd
REXR-C Rexford Industrial Realty Inc

Company profile

Cornerstone Strategic Value Fund, Inc. (the Fund) is a closed-end, diversified management investment company. The Fund's investment objective is to seek long-term capital appreciation through investment primarily in equity securities of United States and non-United States companies. The Fund invests in various sectors, such as information technology, health care, consumer discretionary, financials, communication services, closed-end funds, industrials, consumer staples, exchange-traded funds (ETFs), materials, real estate, and others. The Fund invests in companies of all capitalization ranges. The Fund invests in common stocks and also invests in preferred stocks, rights, warrants and securities convertible into common stocks that are listed on stock exchanges or traded over the counter. The Fund also invests without limitation in other closed-end investment companies and ETFs. The Fund's investment manager is Cornerstone Advisors, LLC.


Last Trade
0.00 (0.00%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.0095 (-0.09%)
B/A Size
Day's High
Day's Low

10-day average volume:

Illumina Ventures Announces Promotion and Additions to its Investment Team

8:00 am ET May 24, 2022 (BusinessWire) Print

Illumina Ventures, today announced the promotion of Malek Faham, MD, PhD, to Chief Scientist having previously served as both a Venture Partner and Entrepreneur in Residence (EIR). In addition, Charles Lin, PhD, has joined the team as a Principal, and Dave Johnson, PhD, has joined as an Entrepreneur in Residence.

"Having Malek on our investment team for the last 4 years has been invaluable," said Nick Naclerio, PhD, Illumina Ventures Founding Partner. "As the firm's new Chief Scientist, his role will expand to include identifying emerging trends in genomics, leading scientific diligence on new investments, assisting with new company formations, and contributing to the success of our portfolio companies."

Malek has distinguished himself as both an inventor and an entrepreneur. He has been affiliated with Illumina Ventures since 2017, first as an EIR and then as a Venture Partner. Prior to Illumina Ventures, Malek co-founded and served as CSO of Sequenta Inc., focused on discovering and developing diagnostic tests based on immune cell receptor repertoire sequencing until it was acquired by Adaptive Biotechnologies (NASDAQ: ADPT). Previously, he co-founded and served as CSO for ParAllele Biosciences, whose technologies were used for polymorphism detection and genotyping by multiple pharmaceutical and academic partners, including the HapMap project, until it was acquired by Affymetrix (NASDAQ:AFFX). He also co-founded Vineti and served as a scientific advisor to a number of other privately held genomics companies including Illumina Ventures portfolio company Cernostics, which was recently acquired by Castle Bioscience (NASDAQ: CSTL). Malek received his PhD in Human Genetics, MD, and Psychiatry training from the University of California, San Francisco. He has authored 60 peer-reviewed articles and is an inventor on 40 US-issued patents.

"Adding Charles and Dave gives us additional depth and expertise as we continue to expand our portfolio of genomics and precision health investments," said Wouter Meuleman, PhD, Illumina Ventures Partner.

Charles brings 15 years of experience in the life science and genomics sector, most recently serving as Vice President of Business Development and Marketing at Element Biosciences. Previously at Illumina, he held several scientific roles and led cross-functional teams to develop microarray or sequencing applications for both research and clinical purposes, before transitioning to corporate development to focus on M&A and emerging technology trends. He holds a PhD degree in Chemistry and Chemical Biology from Harvard University and completed his postdoctoral fellowship in cell biology at the Howard Hughes Medical Institute and UC San Diego School of Medicine.

Dave has a strong track record of bringing new life science technologies to the market. He most recently served as Founder and CEO of GigaGen, Inc., a novel platform for single-cell immune genomics that was acquired by Grifols (NASDAQ: GRFS). Previously, he was COO, Senior Vice President of Research and Development at Natera (NASDAQ: NTRA), where he co-invented methods for non-invasive prenatal diagnosis. After earning his PhD degree in Genetics from Stanford University, he completed his MBA from the Haas School of Business at the University of California, Berkeley.

About Illumina Ventures

Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN). As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, and personal wellness. For more information, visit

View source version on

SOURCE: Illumina Ventures">

Valerie Enes, Vice President, Seismic
comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.